Ocugen

Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.

Ocugen
Products and Services / Research

Ocugen Advances in Pioneering Gene Therapy for Geographic Atrophy with DSMB Approval to Proceed to Medium Dose in Clinical Trial

- by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focusing on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced a significant milestone in its Phase 1/2 …

Ocugen Advances in Pioneering Gene Therapy for Geographic Atrophy with DSMB Approval to Proceed to Medium Dose in Clinical Trial Read More


Ocugen
Executives

Ocugen, Inc. Welcomes Dr. Huma Qamar as New Chief Medical Officer to Spearhead Clinical Developments

- by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies, recently announced the appointment of Dr. Huma Qamar as its Chief Medical …

Ocugen, Inc. Welcomes Dr. Huma Qamar as New Chief Medical Officer to Spearhead Clinical Developments Read More
Ocugen
Products and Services / Research

Ocugen’s Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the Horizon

- by Timothy Alexander

MALVERN, PA — Ophthalmology is on the crest of a wave; a paradigm shift heralded by Ocugen, Inc (NASDAQ: OCGN) may be imminent. The Pennsylvania-based biopharmaceutical firm recently crossed a …

Ocugen’s Revolutionary Gene Therapy Targets Geographic Atrophy: A Shift in Ophthalmology on the Horizon Read More